Given an estimated 230,000 new cases of breast cancer in 2015, this means it is likely that 4600 or more of these are IBC. It may be scattered throughout the breast parenchyma (lobules/ducts).
Dawood and Cristofanilli provide a concise review of inflammatory breast cancer (IBC) and succinctly cover its most salient features, including its clinicopathologic characteristics, its key molecular features, and an overview of treatment outcomes. Dawood and Cristofanilli) after the meeting of the First International Conference on Inflammatory Breast Cancer. Potential challenges in the capture of precise data on IBC for research purposes can also arise because of recent changes in the coding requirements of tumor registries. Breast cancer is a major cause of morbidity and mortality in the world (1).A rare (~6% of all cases) but often lethal form of locally advanced breast cancer is inflammatory breast cancer (IBC).IBC is a form of locally advanced breast cancer (LABC) that was first described by Lee and Tannenbaum in 1924 (2).In this review we address a lesser-known, positive role for E-cadherin in cancer.Germline or somatic mutations in the E-cadherin gene ( or downregulation by epigenetic mechanisms have been described in a small subset of epithelial cancers.Because of its relative scarcity and difficulty for obtaining diagnostic samples of sufficient size, the molecular basis of IBC still waits clarification (4).Micro RNAs (mi RNAs/mi Rs) are a class of non-coding RNAs able to regulate gene expression at the post-transcriptional level, by binding to the 3′-untranslated region of target messenger RNAs (m RNAs) through partial sequence homology, and causing a block of translation and/or m RNA degradation (6–8).In the context of cancer, E-cadherin has traditionally been categorized as a tumor suppressor, given its essential role in the formation of proper intercellular junctions, and its downregulation in the process of epithelial-mesenchymal transition (EMT) in epithelial tumor progression.Germline or somatic mutations in the E-cadherin gene (CDH1) or downregulation by epigenetic mechanisms have been described in a small subset of epithelial cancers.